Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy (Samis J et al. Pediatr Blood Cancer, July 2017)

Pediatr Blood Cancer, July 2017 
Samis J et al

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia (Ernst T et al. Leukemia, June 2018)

Leukemia, June 2018 
Ernst T et al. 

Death within 1 month of diagnosis in childhood cancer: an analysis of risk factors and scope of the problem (Green A et al. J Clin Oncol, March 2017)

J Clin Oncol, March 2017 
Green A et al

Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (Millot F et al. Cancer, May 2017)

Cancer, May 2017 
Millot F et al

Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib (Shima H et al. Pediatr Blood Cancer, February 2017)

Pediatr Blood Cancer, February 2017
Shima H et al.  


Abstract

Bone marrow samples of newly diagnosed children with chronic-phase chronic myeloid leukemia (CML) were obtained at diagnosis and after imatinib initiation and stained with anti-human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and elevated cMpl expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic-phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.

 


© 2017 Wiley Periodicals, Inc.

  1. Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukemia with bone marrow fibrosis (Hussein K et al. Leukemia, February 2017)
  2. Optimal management for pediatric chronic myeloid leukemia (Tanzizawe A. Pediatrics International, March 2016)
  3. Early response does not predict outcome in children and adolescents with chronic myeloid leukemia treated with high-dose imatinib (Giona F et al. Br J Haematol, Dec 2016)
  4. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy (Proschmann R et al. Haematologica, November 2016)